On 24th September, Generate:Biomedicines announced that it has struck a deal with Novartis to develop an undisclosed number of targets in various disease areas. With milestone payments, the company is eligible to receive over $1 billion, in addition to royalties. Novartis is paying Generate $65 million up front, which includes $15 million for an undisclosed amount of equity in the company. The partnership revolves around Generate’s generative AI platform, which integrates machine learning with high-throughput experimental validation with the aim of ushering in a new era of programmable biology.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission.
Dec 13, 2024
